Saskia Pret 4/1/25 Saskia Pret 4/1/25 VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer Read More Saskia Pret 12/16/24 Saskia Pret 12/16/24 VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO Read More Saskia Pret 7/9/24 Saskia Pret 7/9/24 VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board Read More Saskia Pret 6/17/24 Saskia Pret 6/17/24 UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study Read More Saskia Pret 6/14/24 Saskia Pret 6/14/24 VectorY to participate in key sector events in June 2024 Read More Saskia Pret 1/18/24 Saskia Pret 1/18/24 VectorY appoints Khurem Farooq to Board of Directors Read More Saskia Pret 11/13/23 Saskia Pret 11/13/23 VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases Read More Saskia Pret 5/1/23 Saskia Pret 5/1/23 VectorY to Present at the ASGCT Annual Meeting in May 2023 Read More Sariette Witte 4/14/23 Sariette Witte 4/14/23 VectorY to Present at the Bio€quity Europe Conference in May Read More Sariette Witte 4/5/23 Sariette Witte 4/5/23 VectorY to Participate in Key Sector Conferences in April 2023 Read More Sariette Witte 3/20/23 Sariette Witte 3/20/23 VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors Read More Sariette Witte 1/19/23 Sariette Witte 1/19/23 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters Read More Sariette Witte 1/10/23 Sariette Witte 1/10/23 Launching VectorY’s new corporate identity Read More BRONS + TEN KATE 11/8/22 BRONS + TEN KATE 11/8/22 VectorY Appoints Sander van Deventer as CEO and makes Key Appointments to its Leadership Team Read More BRONS + TEN KATE 10/26/22 BRONS + TEN KATE 10/26/22 VectorY to Participate in the Jefferies and JP Morgan Healthcare Conferences Read More BRONS + TEN KATE 10/7/22 BRONS + TEN KATE 10/7/22 VectorY Announces Participation in Scientific Conferences in October 2022 Read More BRONS + TEN KATE 8/23/22 BRONS + TEN KATE 8/23/22 VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA Read More BRONS + TEN KATE 6/15/22 BRONS + TEN KATE 6/15/22 Cell & Gene Meeting on the Med 2022 & Cell & Gene Meeting on the Mesa 2021 Read More BRONS + TEN KATE 5/20/22 BRONS + TEN KATE 5/20/22 VectorY presents 2 posters on the pre-clinical development of VTx-001 and VTx-002 at the American Society of Gene and Cell Therapy Congress 2022 Annual Meeting, May 16-19 in Washington, D.C. Read More BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”. Read More Older Posts
Saskia Pret 4/1/25 Saskia Pret 4/1/25 VectorY Therapeutics Appoints Olga Uspenskaya-Cadoz as Chief Medical Officer Read More
Saskia Pret 12/16/24 Saskia Pret 12/16/24 VectorY Strengthens Leadership Team with appointment of Jim Scibetta as new CEO Read More
Saskia Pret 7/9/24 Saskia Pret 7/9/24 VectorY Appoints Seasoned Biotech Leader Adam Rosenberg as Chair of the Board Read More
Saskia Pret 6/17/24 Saskia Pret 6/17/24 UMC Utrecht and VectorY Therapeutics collaborate in ALS Biomarker Study Read More
Saskia Pret 6/14/24 Saskia Pret 6/14/24 VectorY to participate in key sector events in June 2024 Read More
Saskia Pret 1/18/24 Saskia Pret 1/18/24 VectorY appoints Khurem Farooq to Board of Directors Read More
Saskia Pret 11/13/23 Saskia Pret 11/13/23 VectorY Raises €129 Million ($138 Million) Series A Financing to Advance Vectorized Antibody Programs in Neurodegenerative Diseases Read More
Saskia Pret 5/1/23 Saskia Pret 5/1/23 VectorY to Present at the ASGCT Annual Meeting in May 2023 Read More
Sariette Witte 4/14/23 Sariette Witte 4/14/23 VectorY to Present at the Bio€quity Europe Conference in May Read More
Sariette Witte 4/5/23 Sariette Witte 4/5/23 VectorY to Participate in Key Sector Conferences in April 2023 Read More
Sariette Witte 3/20/23 Sariette Witte 3/20/23 VectorY Appoints Michael Wyzga as CFO and adds Jean Franchi to its Board of Directors Read More
Sariette Witte 1/19/23 Sariette Witte 1/19/23 VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters Read More
BRONS + TEN KATE 11/8/22 BRONS + TEN KATE 11/8/22 VectorY Appoints Sander van Deventer as CEO and makes Key Appointments to its Leadership Team Read More
BRONS + TEN KATE 10/26/22 BRONS + TEN KATE 10/26/22 VectorY to Participate in the Jefferies and JP Morgan Healthcare Conferences Read More
BRONS + TEN KATE 10/7/22 BRONS + TEN KATE 10/7/22 VectorY Announces Participation in Scientific Conferences in October 2022 Read More
BRONS + TEN KATE 8/23/22 BRONS + TEN KATE 8/23/22 VectorY to Present Poster on Huntington’s Preclinical Data at the Hereditary Disease Foundation, August 24-27 in Cambridge, MA Read More
BRONS + TEN KATE 6/15/22 BRONS + TEN KATE 6/15/22 Cell & Gene Meeting on the Med 2022 & Cell & Gene Meeting on the Mesa 2021 Read More
BRONS + TEN KATE 5/20/22 BRONS + TEN KATE 5/20/22 VectorY presents 2 posters on the pre-clinical development of VTx-001 and VTx-002 at the American Society of Gene and Cell Therapy Congress 2022 Annual Meeting, May 16-19 in Washington, D.C. Read More
BRONS + TEN KATE 5/18/22 BRONS + TEN KATE 5/18/22 VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”. Read More
